Promises and pitfalls of anti-angiogenic therapy in clinical trials (Q35076995)

6 August 2017

1 reference

title

Promises and pitfalls of anti-angiogenic therapy in clinical trials (English)

1 reference

6 August 2017

main subject

angiogenesis inhibitor

1 reference

Marya F McCarty

1

1 reference

6 August 2017

Wenbiao Liu

2

1 reference

6 August 2017

Fan Fan

3

1 reference

6 August 2017

Alex Parikh

4

1 reference

6 August 2017

Niels Reimuth

5

1 reference

6 August 2017

Oliver Stoeltzing

6

1 reference

6 August 2017

Lee M Ellis

7

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Trends in Molecular Medicine

6 August 2017

published in

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

53-58

1 reference

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Developmental roles of platelet-derived growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Platelet‐derived growth factor‐B increases colon cancer cell growth in vivo by a paracrine effect

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Integrins: versatility, modulation, and signaling in cell adhesion

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

The extracellular matrix as a cell survival factor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Endostatin binds to the catalytic domain of matrix metalloproteinase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Angiostatin binds ATP synthase on the surface of human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Expression of thrombospondin-1 in cancer: a role in tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

New strategies in anti-vascular cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Tumor regression by targeted gene delivery to the neovasculature

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Endothelial cell heterogeneity and organ specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Effect of p53 status on tumor response to antiangiogenic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

HIF-1 and tumor progression: pathophysiology and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Angiogenesis induced by urothelial cells (HCV-29) and their v-ras and v-raf transfectants

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900002-9

7 January 2021

10.1016/S1471-4914(03)00002-9

Identifiers

DOI

1 reference

6 August 2017

1 reference